Structure-based screening and a conformational biosensor identify a GPR183 inverse agonist and an activation switch.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42218170.
- Also identified by DOI 10.1038/s41467-026-73857-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GPR183 is a chemotactic GPCR involved in immune cell migration. Using AI-driven virtual screening and biophysical assays, we identify inverse agonists. From 70 compounds and a subsequent hit expansion, compound 78 emerges as a potent inhibitor of constitutive and agonist-induced Gi signaling as well as β-arrestin2 recruitment. Binding within the receptor core is confirmed by a conformational biosensor, molecular dynamics simulations, and mutagenesis. The compound also blocks agonist-driven migration of peripheral blood mononuclear cells ex vivo with very high potency. Additionally, our analyses reveal key features of GPR183 activation, highlighting tyrosine 260 (Y260<sup>6.51</sup>) in transmembrane helix 6 as critical. Mutation of this residue alters compound 78 efficacy as well as induces receptor signaling bias, indicating a switch mechanism. Overall, this study provides tools to probe GPR183 function, identifies a chemical scaffold, and advances understanding of receptor activation, supporting therapeutic targeting in inflammatory, autoimmune, and cancer-related diseases.